These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18617547)

  • 1. Electrophysiological effects of intravitreal Avastin (bevacizumab) in the treatment of exudative age-related macular degeneration.
    Karanjia R; Eng KT; Gale J; Sharma S; ten Hove MW
    Br J Ophthalmol; 2008 Sep; 92(9):1248-52. PubMed ID: 18617547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration.
    Pedersen KB; Møller F; Sjølie AK; Andréasson S
    Retina; 2010; 30(7):1025-33. PubMed ID: 20616681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB; Sjølie AK; Møller F
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F
    Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration.
    Krebs I; Lie S; Stolba U; Zeiler F; Felke S; Binder S
    Acta Ophthalmol; 2009 Sep; 87(6):611-7. PubMed ID: 18937801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased electroretinogram a-wave amplitude after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Skaat A; Solomon A; Moroz I; Hai OV; Rechtman E; Vishnevskia Dai V; Rotenstreich Y
    Acta Ophthalmol; 2011 May; 89(3):e269-73. PubMed ID: 20946333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment.
    Maturi RK; Bleau LA; Wilson DL
    Retina; 2006 Mar; 26(3):270-4. PubMed ID: 16508425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of bevacizumab (Avastin) injection in patients with age-related macular degeneration and low visual acuity.
    Ehrlich R; Weinberger D; Priel E; Axer-Siegel R
    Retina; 2008 Oct; 28(9):1302-7. PubMed ID: 18664935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early multifocal electroretinogram findings during intravitreal ranibizumab treatment for neovascular age-related macular degeneration.
    Campa C; Hagan R; Sahni JN; Brown MC; Beare NA; Heimann H; Harding SP
    Invest Ophthalmol Vis Sci; 2011 Jun; 52(6):3446-51. PubMed ID: 21357390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
    Tao Y; Jonas JB
    Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
    Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration.
    Ozdemir H; Karacorlu M; Senturk F; Karacorlu SA; Uysal O
    Acta Ophthalmol; 2012 Feb; 90(1):71-5. PubMed ID: 20163371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
    Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration.
    Jonas JB; Ihloff AK; Harder B; Kreissig I; Schlichtenbrede F; Libondi T; Spandau UH; Vossmerbaeumer U
    Ophthalmic Res; 2009; 41(1):21-7. PubMed ID: 18849638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration.
    Jonas JB; Libondi T; Golubkina L; Spandau UH; Schlichtenbrede F; Rensch F
    Acta Ophthalmol; 2010 Sep; 88(6):630-4. PubMed ID: 19432871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.